Kurve Therapeutics
About this raise
Kurve Therapeutics is raising funds through Reg A+ crowdfunding with Rialto Markets as the Broker-Dealer. The company has developed its patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology. The technology creates a focused flow through the curved pathways of the nasal cavity and allows access to the olfactory region to treat neurogenerative diseases. Kurve Therapeutics’ technology has been featured in multiple publications and has completed Phase II studies on Alzheimer’s patients. Marc Giroux, Tom McDowell, and Glenn Cornett founded Kurve Therapeutics in 2019. The current crowdfunding campaign has a maximum target of $50,000,000. The campaign proceeds will be used for asset purchase, marketing, clinical studies, contract manufacturing, and working capital.
Investment Overview
Deal Terms
- Platform
- Rialto Markets
- Start Date
- 08/03/2022
- Close Date
- 09/29/2023
$580
$50,000,000
$580
Equity - Common
Growth Stage
RegA+
$5.80
$291,787,299
Company & Team
Company
- Year Founded
- 2019
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Analyst Report
No company has been able to develop an FDA-approved treatment that stops Alzheimer's in its tracks. Kurve Therapeutics has the potential to change that with its potentially groundbreaking device. But its long road to FDA approval and its inexperienced team may threaten the company's survival.
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $10,000,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 09/29/2023 | Rialto Markets | $291,787,299 | - | Equity - Common | Funded | RegA+ |
Founder Interview
Kurve Therapeutics Founder Marc Giroux on Treating Alzheimer’s and More
The central nervous system (CNS) disorder umbrella houses a number of familiar names, like Alzheimer’s, Parkinson’s, and multiple sclerosis. These conditions are often life-altering to sufferers, and many are incurable. Thankfully, treatments are available, and scientists aren’t done looking for new solutions.Kurve Therapeutics is fighting CNS disorders right up the nose with its patented Controlled Particle Dispersion technology. This intranasal technology delivers drugs noninvasively and painlessly, and it makes treatments more precise and effective. We reached out to founder and CEO Marc Giroux to hear about why he originally started working on the technology and how Kurve Therapeutics overcame assumptions.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.